{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-119245","form_type":"8-K","ticker":"KYMR","cik":"0001815442","company_name":"Kymera Therapeutics, Inc.","filed_at":"2024-10-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.785843+00:00","generated_at":"2026-05-30T07:37:05.834247+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Kymera posts Q3 net loss $62.5M; initiates STAT6 degrader Phase 1; shifts focus to immunology","bullets":["Net loss $62.5M in Q3 2024 vs $52.9M in Q3 2023; collaboration revenue $3.7M from Sanofi.","Initiated Phase 1 dosing for KT-621 (STAT6 degrader); Phase 1 data expected H1 2025.","Sanofi expands KT-474 (IRAK4) Phase 2 HS/AD trials to dose-ranging Phase 2b; primary completion mid-2026.","Selected KT-295 (TYK2 degrader) as development candidate; Phase 1 start in H1 2025.","Cash $911M as of Sep 30, 2024; runway into mid-2027; will only advance oncology with partner."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-119245","json":"https://secwatch.observer/filing/0000950170-24-119245.json","markdown":"https://secwatch.observer/filing/0000950170-24-119245.md","text":"https://secwatch.observer/filing/0000950170-24-119245.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815442/000095017024119245/0000950170-24-119245-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815442/000095017024119245/kymr-20241031.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T07:37:05.834247+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}